Metabolic maintenance of breast cancer cells and metastases throughE-cadherin/YAP-dependent pyruvate carboxylase expression

This study reveals that E-cadherin maintains mitochondrial oxidative metabolism and protects breast cancer cells from oxidative stress by activating the AKT-YAP/TEAD signaling pathway to upregulate pyruvate carboxylase, a mechanism that supports metastasis and represents a promising therapeutic target.

The Gist

The Big Picture: A Metabolic Switch in Cancer Cells

Imagine breast cancer cells as rogue construction crews. Usually, when these crews get aggressive and start spreading (metastasis), they are thought to "shed their skin," becoming messy, individual wanderers (a process called EMT) that rely on a fast, dirty energy source (sugar fermentation) to survive.

However, this study discovered a surprising twist: Many of the most dangerous, spreading cancer cells actually keep their "skin" on. They stay connected to each other like a tight-knit team, and they switch to a high-efficiency, clean-burning engine (mitochondria) to power their spread.

The researchers found out how they do this and, more importantly, found a way to break their engine.

---

The Key Characters and Their Roles

1. E-Cadherin: The "Velcro"

Think of E-cadherin as the Velcro that holds cancer cells together.

• Old Belief: Scientists used to think losing this Velcro was the only way cancer could spread.
• New Discovery: These aggressive cancer cells keep the Velcro. They stay in tight clusters (like a group of friends holding hands), and this connection is actually what supercharges their energy.

2. The Engine: Mitochondria & Pyruvate Carboxylase (PC)

Inside the cell, there is a power plant called the mitochondria. To run this plant efficiently, the cell needs a specific fuel processor called Pyruvate Carboxylase (PC).

• The Analogy: If the cell is a car, the mitochondria are the engine, and PC is the turbocharger.
• The Finding: The "Velcro" (E-cadherin) tells the cell to turn on the turbocharger (PC). This allows the cancer cells to burn fuel cleanly and efficiently, giving them the stamina to travel through the blood and set up new colonies in the lungs.

3. The Signal Chain: The "Manager" and the "Foreman"

How does the Velcro tell the turbocharger to turn on? It uses a chain of command:

1. E-Cadherin (Velcro) senses that cells are touching.
2. It wakes up a Manager called AKT.
3. The Manager signals a Foreman called YAP.
4. The Foreman goes to the cell's "instruction manual" (DNA) and flips the switch to build more Turbochargers (PC).

---

The Experiment: How They Proved It

The researchers used a clever trick to study these cells. Instead of growing them flat on a dish (2D), they grew them in floating, 3D balls called "emboli."

• The Analogy: Imagine studying a school of fish. If you look at them in a flat tank, they swim differently than when they are swimming together in a school. The 3D balls mimic how cancer cells actually travel in the body.

What they found:

• When they removed the Velcro (E-cadherin), the cells lost their turbocharger (PC). Their engine sputtered, they couldn't handle stress, and they struggled to survive.
• When they forced the turbocharger (PC) to stay on, even without the Velcro, the cells survived and kept running.
• The "Smoking Gun": They used a drug (ZY-444) that acts like a wrench thrown into the turbocharger. When they threw this wrench at the cancer cells, the engine stopped. The cells couldn't grow or spread.

---

The Real-World Test: Stopping the Invasion

The researchers didn't just stop at the petri dish. They tested this on mice with lung metastases (cancer that had already spread to the lungs).

• The Setup: They injected cancer cells into mice. Once the tumors were established in the lungs, they gave half the mice a placebo and the other half the "wrench" drug (ZY-444).
• The Result: The mice treated with the drug saw their lung tumors shrink or stop growing. The drug worked as a standalone treatment, even though the cancer had already spread.

---

Why This Matters: A New Way to Fight Cancer

This study changes the game in two big ways:

1. It challenges the "Old Rules": We thought cancer had to become "loose and messy" to spread. This study shows that staying "tight and connected" (keeping E-cadherin) is actually a superpower for some aggressive cancers because it fuels their energy.
2. It offers a new weapon: Since these cancer cells rely heavily on this specific turbocharger (PC) to survive, we can target it.
   • The Strategy: Instead of just trying to kill the cell, we can cut off its fuel supply.
   • The Future: Drugs that block this "Velcro-to-Turbocharger" pathway (or the wrench drug itself) could be a new way to treat aggressive breast cancers, especially those that have already spread to the lungs.

In a Nutshell

The cancer cells are like a high-performance sports car that stays in a tight convoy. The "Velcro" holding them together tells the engine to rev up. If you can jam the engine (by blocking the PC turbocharger), the convoy stops, and the cancer can't spread. This opens the door to new, targeted therapies for patients with metastatic breast cancer.

Technical Summary

1. Problem Statement

• The Paradox of E-cadherin: Epithelial-mesenchymal transition (EMT) is traditionally viewed as a driver of cancer metastasis, characterized by the loss of E-cadherin. However, clinical data shows that most aggressive breast cancers (including Inflammatory Breast Cancer and Triple-Negative Breast Cancer) and their metastases retain E-cadherin expression. The mechanisms by which E-cadherin contributes to metastatic progression in these epithelial-predominant tumors remain poorly understood.
• Metabolic Uncertainty: While the Warburg effect (aerobic glycolysis) is linked to EMT, mitochondrial oxidative phosphorylation (OXPHOS) is increasingly recognized as crucial for metastatic competence and chemoresistance. The causal link between E-cadherin expression, mitochondrial metabolism, and the specific enzymes driving this process in breast cancer is undefined.
• Therapeutic Gap: There is a lack of targeted therapies for metastatic breast cancers that retain epithelial characteristics, particularly those dependent on mitochondrial metabolism.

2. Methodology

The study employed a multi-faceted approach combining 3D cell culture, molecular biology, pharmacological inhibition, and in vivo models:

• 3D "Emboli" Culture (EmC): The authors utilized a specialized 3D culture model using viscous media and orbital rocking to form stable multicellular aggregates (emboli). This model recapitulates in vivo ultrastructural features (nuclei, mitochondria, lipid droplets) and cell-cell adhesions better than 2D cultures.
• Cell Lines: The study focused on epithelial breast cancer cell lines (SUM149, MDA-MB-468, IBC-3) and mesenchymal lines (MDA-MB-231-LM2, SUM159).
• Genetic Manipulation:
  • Knockdown: Stable shRNA-mediated silencing of CDH1 (E-cadherin) and YAP.
  • Overexpression: Transient ectopic expression of E-cadherin and Pyruvate Carboxylase (PC).
• Pharmacological Interventions:
  • ZY-444: A specific small-molecule inhibitor of Pyruvate Carboxylase (PC).
  • IK-930: A TEAD inhibitor disrupting YAP/TAZ-TEAD interaction.
  • MK2206 & LY294002: AKT and PI3K inhibitors, respectively.
• Metabolic Assays: Seahorse XF Analyzer was used to measure Oxygen Consumption Rate (OCR) for OXPHOS and Extracellular Acidification Rate (ECAR) for glycolysis. Reactive Oxygen Species (ROS) were measured via DCF fluorescence.
• Molecular Analysis: Western blotting, qRT-PCR, Chromatin Immunoprecipitation (ChIP) for TEAD binding, and luciferase reporter assays.
• Clinical Correlation: Multiplex immunofluorescence on Human Tissue Microarrays (TMA) and experimental lung metastases in mice to assess co-expression of E-cadherin and PC.
• In Vivo Metastasis Model: A tail-vein injection model in NSG mice using luciferase-expressing SUM149 cells to monitor established lung metastases via bioluminescence imaging (BLI) and histological analysis.

3. Key Contributions & Results

A. E-cadherin Drives Mitochondrial Metabolism and Reduces Oxidative Stress

• Finding: In 3D EmC, silencing E-cadherin significantly reduced the Oxygen Consumption Rate (OCR) and the OCR/ECAR ratio, indicating a shift away from OXPHOS.
• Consequence: E-cadherin-depleted cells exhibited increased ROS levels (oxidative stress) and reduced viability in 3D aggregates.
• Significance: This establishes a direct causal role for E-cadherin in maintaining mitochondrial respiration and protecting epithelial cancer cells from oxidative stress.

B. Identification of Pyruvate Carboxylase (PC) as the Key Effector

• Finding: Proteomic and transcriptomic analysis revealed that E-cadherin upregulates Pyruvate Carboxylase (PC), an anaplerotic enzyme converting pyruvate to oxaloacetate to feed the TCA cycle.
• Validation:
  • E-cadherin knockdown reduced PC mRNA and protein levels.
  • Ectopic E-cadherin expression in mesenchymal cells induced PC.
  • Rescue Experiment: Overexpressing PC in E-cadherin-silenced cells restored OCR, reduced ROS, and improved cell survival, proving PC is the functional downstream effector.
• Clinical Relevance: Co-expression of E-cadherin and PC was confirmed in experimental lung metastases and human breast cancer tissue samples (TNBC, HER2+, and ER+ subtypes).

C. Elucidation of the Signaling Pathway: E-cadherin → AKT → YAP/TEAD → PC

• Mechanism: The study mapped a novel signaling axis:
  1. E-cadherin activates AKT (via phosphorylation).
  2. Active AKT prevents the degradation of YAP (Yes-associated protein), allowing it to translocate to the nucleus.
  3. Nuclear YAP binds to TEAD transcription factors.
  4. The YAP/TEAD complex binds to a consensus site on the PC promoter, driving its transcription.
• Evidence:
  • Inhibiting AKT (MK2206) or TEAD (IK-930) reduced PC expression and OXPHOS.
  • ChIP assays confirmed TEAD binding to the PC promoter, which was lost upon YAP silencing.
  • Mechanical stimulation (rocking in EmC) was required for full PC induction, linking mechanotransduction to this metabolic program.

D. Therapeutic Efficacy of PC Inhibition

• In Vivo Results: Treatment of mice with established SUM149 lung metastases with ZY-444 (PC inhibitor) significantly attenuated tumor burden and reduced bioluminescent signals compared to controls.
• Implication: PC inhibition is effective even against established metastases, suggesting it targets a vulnerability in the metastatic niche rather than just initial colonization.

4. Significance and Implications

• Reframing E-cadherin's Role: The study challenges the dogma that E-cadherin is solely a tumor suppressor. Instead, in the context of 3D aggregates and mechanical stress, it acts as an oncogenic driver by sustaining mitochondrial metabolism via the AKT-YAP-PC axis.
• Metabolic Vulnerability: It identifies Pyruvate Carboxylase as a critical metabolic dependency for epithelial breast cancer metastases. Unlike normal breast epithelium, which lacks PC, breast cancer cells (especially metastatic ones) are highly dependent on it.
• Therapeutic Strategy:
  • Direct Targeting: PC inhibition (e.g., ZY-444) represents a viable monotherapy for metastatic epithelial breast cancers.
  • Pathway Targeting: Existing AKT and TEAD inhibitors may exert anti-cancer effects partly through metabolic reprogramming (downregulating PC).
  • Combination Therapy: Since this pathway protects against oxidative stress, combining PC inhibitors with ROS-inducing agents could yield synergistic effects.
• Biomarker Potential: The co-expression of E-cadherin and PC could serve as a biomarker to stratify patients likely to respond to metabolic or upstream pathway inhibitors.

Conclusion

This paper defines a mechanistic link between cell-cell adhesion (E-cadherin), mechanotransduction (YAP/TEAD), and metabolic reprogramming (PC) that fuels breast cancer metastasis. By demonstrating that inhibiting PC attenuates established metastases, the authors identify a promising therapeutic avenue for aggressive, epithelial-predominant breast cancers that have historically been difficult to treat.